株探米国株
英語
エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
___________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report: April 23, 2026
(Date of earliest event reported)
 
BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)
 
Nevada
001-37603
30-1341024
(State or Other Jurisdiction of Incorporation)
(Commission File No.)
(IRS Employer Identification Number)
 
40 Marcus Drive, Melville, New York
    11747
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant's telephone number, including area code: (631) 760-8100
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
___
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
___
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
___
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
___
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)

Name of each exchange on which registered
Common Stock, $0.0001 par value
BRTX
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ____
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Item 7.01
Regulation FD Disclosure.
 
___ On April 23, 2026, BioRestorative Therapies, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that may be used by the Company in connection with presentations at conferences and investor meetings. The Presentation can be found on the Company’s website, www.biorestorative.com. The Presentation is furnished as Exhibit 99.1 hereto.
The information in the Presentation is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Presentation will not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.  The furnishing of the information in this Current Report on Form 8-K with respect to the Presentation is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Presentation is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
 
Item 9.01
Financial Statements and Exhibits.
 
(d)
Exhibits.
 
Number
Description
 
 
99.1
Presentation Materials
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: April 23, 2026
BIORESTORATIVE THERAPIES, INC.
 
 
 
By: /s/ Robert Kristal
 
Robert Kristal
 
Chief Financial Officer
 
 
 
 
 
 
                    
 
 
 
 
 
 
                    
 
 
NY 0001505497 false 0001505497 2026-04-23 2026-04-23
EX-99.1 5 ex99.htm EX-99.1 PRESENTATION MATERIALS
ex99.pdf page 1
ex99.pdf page 2
ex99.pdf page 3
ex99.pdf page 4
ex99.pdf page 5
ex99.pdf page 6
ex99.pdf page 7
ex99.pdf page 8
ex99.pdf page 9
ex99.pdf page 10
ex99.pdf page 11
ex99.pdf page 12
ex99.pdf page 13
ex99.pdf page 14
ex99.pdf page 15
ex99.pdf page 16
ex99.pdf page 17
ex99.pdf page 18
ex99.pdf page 19
ex99.pdf page 20
ex99.pdf page 21
ex99.pdf page 22
ex99.pdf page 23
ex99.pdf page 24
ex99.pdf page 25
ex99.pdf page 26
ex99.pdf page 27
ex99.pdf page 28
ex99.pdf page 29
ex99.pdf page 30
ex99.pdf page 31
ex99.pdf page 32
ex99.pdf page 33
ex99.pdf page 34
ex99.pdf page 35
ex99.pdf page 36
ex99.pdf page 37